Motavizumab - Next gen biotech blockbusters

Drug: Motavizumab
Company: MedImmune/AstraZeneca

Scoop: When AstraZeneca spent $15.6 billion to acquire MedImmune, it picked up motavizumab in the process. Motavizumab, to be sold as Numax, is a fully humanized monoclonal antibody to prevent respiratory syncytial virus infection in infants--a condition which sends about 125,000 infants to the hospital each year. A BLA was submitted back in February and an FDAdecision is expected sometime this year.

Motavizumab - Next gen biotech blockbusters
Read more on

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.